Shuttle Pharmaceuticals logo

Shuttle PharmaceuticalsNASDAQ: SHPH

Profile

Sector:

Healthcare

Country:

United States

IPO:

31 August 2022

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$3.52 M
-99%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector
-126%vs. 3y high
7%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 21:53:58 GMT
$0.96-$0.01(-1.01%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

SHPH Latest News

Shuttle Pharma Provides Third Quarter 2024 Corporate Update
globenewswire.com13 November 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024.

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
globenewswire.com28 October 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma following the entry into agreements with Georgetown University Medical Center and UNC Medical Center. The Company previously entered agreements with UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida. Patients are currently undergoing screening for enrollment in the trial.

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
globenewswire.com16 September 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida.

Shuttle Pharma Provides Second Quarter 2024 Corporate Update
globenewswire.com04 September 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024.

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
globenewswire.com14 August 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial.

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
globenewswire.com19 July 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
GlobeNewsWire03 April 2024 Sentiment: POSITIVE

GAITHERSBURG, Md., April 03, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference.

What type of business is Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

What sector is Shuttle Pharmaceuticals in?

Shuttle Pharmaceuticals is in the Healthcare sector

What industry is Shuttle Pharmaceuticals in?

Shuttle Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Shuttle Pharmaceuticals from?

Shuttle Pharmaceuticals is headquartered in United States

When did Shuttle Pharmaceuticals go public?

Shuttle Pharmaceuticals initial public offering (IPO) was on 31 August 2022

What is Shuttle Pharmaceuticals website?

https://www.shuttlepharma.com

Is Shuttle Pharmaceuticals in the S&P 500?

No, Shuttle Pharmaceuticals is not included in the S&P 500 index

Is Shuttle Pharmaceuticals in the NASDAQ 100?

No, Shuttle Pharmaceuticals is not included in the NASDAQ 100 index

Is Shuttle Pharmaceuticals in the Dow Jones?

No, Shuttle Pharmaceuticals is not included in the Dow Jones index

When was Shuttle Pharmaceuticals the previous earnings report?

No data

When does Shuttle Pharmaceuticals earnings report?

The next expected earnings date for Shuttle Pharmaceuticals is 21 March 2025